Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis
CD206 is a common marker of a putative immunosuppressive "M2" state in tumor-associated macrophages (TAMs). We made a novel conditional CD206 (Mrc1) knock-in mouse to specifically visualize and/or deplete CD206+ TAMs. Early depletion of CD206+ macrophages and monocytes (Mono/Macs) led to the indirect loss of conventional type I dendritic cells (cDC1), CD8 T cells, and NK cells in tumors. CD206+ TAMs robustly expressed CXCL9, contrasting with stress-responsive Spp1-expressing TAMs and immature monocytes, which became prominent with early depletion. CD206+ TAMs differentially attracted activated CD8 T cells, and the NK and CD8 T cells in CD206-depleted tumors were deficient in Cxcr3 and cDC1-supportive Xcl1 and Flt3l expressions. Disrupting this key antitumor axis decreased tumor control by antigen-specific T cells in mice. In human cancers, a CD206Replete, but not a CD206Depleted Mono/Mac gene signature correlated robustly with CD8 T cell, cDC1, and NK signatures and was associated with better survival. These findings negate the unqualified classification of CD206+ "M2-like" macrophages as immunosuppressive.
Authors
- Kelly Kersten (ORCID: https://orcid.org/0000-0001-7615-2594)
- Matthew F. Krummel (ORCID: https://orcid.org/0000-0001-7915-3533)
- Nicholas F. Kuhn (ORCID: https://orcid.org/0000-0001-5634-0846)
- Kenneth H. Hu (ORCID: https://orcid.org/0000-0002-0294-0202)
- Bushra Samad (ORCID: https://orcid.org/0000-0002-2893-0897)
- Alexis J. Combes (ORCID: https://orcid.org/0000-0002-9110-6542)
- Arja Ray (ORCID: https://orcid.org/0000-0003-2305-2324)
- Tristan Courau (ORCID: https://orcid.org/0000-0003-1819-9516)
- Itzia Zaleta-Linares
Institutions
- University of California, San Francisco (US)
Publication Details
- Journal
- The Journal of Experimental Medicine
- Published
- 2024-10-31
- DOI
- https://doi.org/10.1084/jem.20240957
- Citations
- 33
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 7.70
Funders
- American Cancer Society
- Cancer Research Institute
- Jean Perkins Foundation
- National Institutes of Health